|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Dupilumab (monoclonal antibody inhibiting IL-4/IL-13 signalling) is approved for use in adolescents aged ≥ 12 years with inadequately controlled moderate-to-severe atopic dermatitis (AD).
|
31595499 |
2020 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
The multifaceted roles of IL-4 and IL-13 in allergic disease development make IL-4Rα an attractive target for treatment strategies, and a neutralizing monoclonal antibody which antagonizes the effects of both IL-4 and IL-13 by blocking the interaction site found in the IL-4 receptor subunit α (IL-4Rα) has been successfully used to treat patients with moderate-to-severe AD.
|
31596502 |
2020 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
HLJDE significantly reduced the clinical symptoms in the AD-like mice by inhibiting eosinophil and mast cell infiltration, suppressing the production of Th2-associated cytokine (IL-4) and pro-inflammatory cytokines (TNF-α).
|
31678637 |
2020 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> Dupilumab, a fully human monoclonal antibody targeting the alpha subunit of IL-4 was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients.
|
31647347 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the recurrent phase of AD, YPFS exhibited both short- and long-term anti-allergic inflammatory efficacy with reduced ear tissue inflammation and decreased IL-4, IL-5, IL-13, and IgE production.
|
30668371 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recently, cases of AA healing during treatment with anti-IL4/IL13 monoclonal antibody dupilumab (D) for AD were reported.
|
31306557 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, fucoidan significantly suppressed the serum levels of IgE and IL-4 in DNFB-induced AD mice.
|
31422184 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
The above results show WDE protected against oxazolone- and DNCB-induced AD in mice by down-regulating the T<sub>H</sub>2-associated cytokine IL-4 and improving skin barrier function and suggest WDE might be useful for the management of atopic dermatitis.
|
31018627 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Dupilumab, a monoclonal antibody that binds to the α subunit of the IL-4 receptor (IL-4Rα) and has been approved for the treatment of adults with severe atopic dermatitis, has been shown in recent phase 3 trials to also have significant clinical benefits in the asthmatic population irrespective of baseline eosinophil counts.
|
30407206 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> Dupilumab is used for treatment of atopic dermatitis through blockade of IL-4 and IL-13 signaling of the Th2 pathway.
|
31132923 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, luteolin 7-<i>O</i>-glucoside, the major active compound of the <i>S. chamaejasme</i> aerial parts EtOH extract, decreased serum IgE and IL-4 levels and transepidermal water loss and increased skin hydration, therefore exhibiting strong anti-atopic dermatitis activity in 2,4-dinitrochlorobenzene-induced atopic dermatitis mice.
|
30273950 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Rare coding variants associated with AD are further enriched in 5 genes (IL-4 receptor [IL4R], IL13, Janus kinase 1 [JAK1], JAK2, and tyrosine kinase 2 [TYK2]) of the IL13 pathway, all of which are targets for novel systemic AD therapeutics.
|
31707051 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this study, we used keratinocytes and AD-like skin equivalent models using Th2 cytokines IL-4 and IL-13.
|
30506356 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We identified a CpG in IL4 associated with serum tIgE levels, supporting a role for Th2 immune mediating mechanisms in AD.
|
31443688 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Dupilumab, a monoclonal antibody blocking the action of IL-4 and IL-13 effectively reduces the symptoms of AD and itch.
|
31505056 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
<b>Importance:</b> While dupilumab has emerged as an effective treatment for moderate-to-severe atopic dermatitis (AD) since its approval in 2017, interleukin-4 and 13 blockade has also demonstrated efficacy in off-label chronic dermatologic conditions.<b>Objective:</b> To identify chronic dermatologic conditions in which dupilumab has demonstrated efficacy.<b>Findings:</b> Thirty-three reports of dupilumab use in non-AD dermatologic conditions were identified through systematic literature review.
|
31693426 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4<sup>+</sup> cells.
|
30727775 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Moreover, treatment with JC3 (10 mg/kg) significantly decreased serum and ear tissues levels of IFN-γ and IL-4 in AD mice.
|
30729380 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Dupilumab, a monoclonal antibody targeting the IL-4 receptor alpha, is the first antibody-based treatment commercially available for the treatment of AD.
|
30768375 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Dupilumab (a monoclonal antibody blocking the shared receptor component for IL-4 and IL-13) is approved for inadequately controlled moderate-to-severe AD and for moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma.
|
31066001 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
The impact of dupilumab, an anti-interleukin (IL) 4 receptor α antibody that inhibits IL-4 and IL-13 signaling, on vaccine responses of patients with atopic dermatitis (AD) is unknown.
|
30092324 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Decreased levels of IFN-γ (Th1) and IL-17 (Th17), IL-4 and IL-13 (Th2) were detected in T cells and the skin tissue from the MSC-Ex treated AD mice.
|
31036853 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
To test this, we analyzed murine bone marrow-derived DCs (BMDCs) stimulated with IL-4, an important cytokine in AD development.
|
31434203 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
The IL-4/13 antagonist dupilumab was approved in 2017 as the first biologic for atopic dermatitis.
|
31145194 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
These provided IL-4, which targeted MCs to expand in the intestine.Duodenal MCs were expanded in AD.
|
31027995 |
2019 |